[1] |
BOHN M K, STEELE S, HALL A, et al. Cardiac biomarkers in pediatrics:an undervalued resource[J]. Clin Chem, 2021, 67(7):947-958.
DOI
URL
|
[2] |
中国医师协会检验医师分会心血管专家委员会. 心肌肌钙蛋白实验室检测与临床应用中国专家共识[J]. 中华医学杂志, 2021, 101(37):2947-2961.
|
[3] |
THYGESEN K, ALPERT J S, JAFFE A S, et al. Fourth universal definition of myocardial infarction(2018)[J]. Circulation, 2018, 138(20):e618-e651.
|
[4] |
BAHADUR K, IJAZ A, SALAHUDDIN M, et al. Determination of high sensitive cardiac troponin I 99th percentile upper reference limits in a healthy Pakistani population[J]. Pak J Med Sci, 2020, 36(6):1303-1307.
DOI
PMID
|
[5] |
CASELLI C, RAGUSA R, PRONTERA C, et al. Distribution of circulating cardiac biomarkers in healthy children:from birth through adulthood[J]. Biomark Med, 2016, 10(4):357-365.
DOI
URL
|
[6] |
CASELLI C, CANGEMI G, MASOTTI S, et al. Plasma cardiac troponin I concentrations in healthy neonates,children and adolescents measured with a high sensitive immunoassay method:high sensitive troponin I in pediatric age[J]. Clin Chim Acta, 2016, 458:68-71.
DOI
URL
|
[7] |
BOHN M K, HIGGINS V, KAVSAK P, et al. High-sensitivity generation 5 cardiac troponin T sex- and age-specific 99th percentiles in the CALIPER cohort of healthy children and adolescents[J]. Clin Chem, 2019, 65(4):589-591.
DOI
PMID
|
[8] |
杨振华, 潘柏申, 许俊堂. 中华医学会检验学会文件心肌损伤标志物的应用准则[J]. 中华检验医学杂志, 2002, 25(3):185-189.
|
[9] |
马丽娟. 心肌损伤标志物在儿童心肌损伤性疾病诊断中的临床价值评估[J]. 中华检验医学杂志, 2015, 38(6):370-372.
|
[10] |
AYDIN S, UGUR K, AYDIN S, et al. Biomarkers in acute myocardial infarction:current perspectives[J]. Vasc Health Risk Manag, 2019, 15:1-10.
DOI
URL
|
[11] |
PAVASINI R, TAVAZZI G, BISCAGLIA S, et al. Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease:systematic review and meta-analysis[J]. Chron Respir Dis, 2017, 14(2):117-126.
DOI
URL
|
[12] |
KULKARNI M, GOKULAKRISHNAN G, PRICE J, et al. Diagnosing significant PDA using natriuretic peptides in preterm neonates:a systematic review[J]. Pediatrics, 2015, 135(2):e510-525.
DOI
URL
|
[13] |
YANG C, MA J, GUO L, et al. NT-Pro-BNP and echocardiography for the early assessment of cardiovascular dysfunction in neonates with sepsis[J]. Medicine(Baltimore), 2022, 101(37):e30439.
|
[14] |
GREEN M D, PARKER D M, EVERETT A D, et al. Cardiac biomarkers associated with hospital length of stay after pediatric congenital heart surgery[J]. Ann Thorac Surg, 2021, 112(2):632-637.
DOI
PMID
|
[15] |
LIN F, ZHENG L, CUI Y, et al. Prognostic value of perioperative NT-proBNP after corrective surgery for pediatric congenital heart defects[J]. BMC Pediatr, 2019, 19(1):497.
DOI
PMID
|
[16] |
ZHENG X, ZHANG Y, LIU L, et al. N-terminal pro-brain natriuretic peptide as a biomarker for predicting coronary artery lesion of Kawasaki disease[J]. Sci Rep, 2020, 10(1):5130.
DOI
PMID
|
[17] |
RODRIGUEZ D, GARCIA-RIVAS G, LARESGOITI-SERVITJE E, et al. B-type natriuretic peptide reference interval of newborns from healthy and pre-eclamptic women:a prospective,multicentre,cross-sectional study[J]. BMJ Open, 2018, 8(10):e022562.
DOI
URL
|
[18] |
中国医师协会检验医师分会心血管专家委员会. B型利钠肽及N末端B型利钠肽前体实验室检测与临床应用中国专家共识[J]. 中华医学杂志, 2022, 102(35):2738-2754.
|
[19] |
张路, 王薇, 钟堃, 等. 中国N末端B型利钠肽原、B型利钠肽和同型半胱氨酸参考区间来源及决定限的分布[J]. 中华心血管病杂志, 2015, 43(11):965-968.
|
[20] |
MCCARTHY C P, JANUZZI J L Jr. Soluble ST2 in heart failure[J]. Heart Fail Clin, 2018, 14(1):41-48.
DOI
PMID
|
[21] |
WANG Y P, WANG J H, WANG X L, et al. Roles of ST2,IL-33 and BNP in predicting major adverse cardiovascular events in acute myocardial infarction after percutaneous coronary intervention[J]. J Cell Mol Med, 2017, 21(11):2677-2684.
DOI
URL
|
[22] |
YANCY C W, JESSUP M, BOZKURT B, et al. 2013 ACCF/AHA guideline for the management of heart failure:executive summary:a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J]. Circulation,2013, 128(16):1810-1852.
DOI
URL
|
[23] |
中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2014[J]. 中华心血管病杂志, 2014, 42(2):98-122.
|
[24] |
OKADA S, YASUDO H, OHNISHI Y, et al. Interleukin-33/ST2 axis as potential biomarker and therapeutic target in Kawasaki disease[J]. Inflammation, 2023, 46(1):480-490.
DOI
|
[25] |
BLANDA V, BRACALE U M, DI TARANTO M D, et al. Galectin-3 in cardiovascular diseases[J]. Int J Mol Sci, 2020, 21(23):9232.
DOI
URL
|
[26] |
CHOW S L, MAISEL A S, ANAND I, et al. Role of biomarkers for the prevention,assessment,and management of heart failure:a scientific statement from the American Heart Association[J]. Circulation, 2017, 135(22):e1054-e1091.
|
[27] |
GOEL H, MELOT J, KRINOCK M D, et al. Heart-type fatty acid-binding protein:an overlooked cardiac biomarker[J]. Ann Med, 2020, 52(8):444-461.
DOI
URL
|
[28] |
PESONEN E, KESKI-NISULA J, PASSOV A, et al. Heart-type fatty acid binding protein and high-dose methylprednisolone in pediatric cardiac surgery[J]. J Cardiothorac Vasc Anesth, 2017, 31(6):1952-1956.
DOI
PMID
|
[29] |
中华医学会儿科学分会心血管学组, 中华医学会儿科学分会心血管学组心肌炎协作组, 中华儿科杂志编辑委员会, 等. 儿童心肌炎诊断建议(2018年版)[J]. 中华儿科杂志, 2019, 57(2):87-89.
|
[30] |
SANDOVAL Y, THYGESEN K. Myocardial infarction type 2 and myocardial injury[J]. Clin Chem, 2017, 63(1):101-107.
DOI
PMID
|
[31] |
中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 高敏心肌肌钙蛋白在急性冠状动脉综合征中的应用中国专家共识[J]. 中华检验医学杂志, 2012, 35(12):1073-1076.
|